CardioKinetix closes enrolment in Parachute China trial to treat heart failure

US-based medical device firm CardioKinetix has completed patient enrolment in Parachute China, a multi-centre trial designed to assess the minimally invasive Parachute Ventricular Partitioning Device to treat heart failure.

Free Report

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.

By GlobalData

By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial enrolled New York Heart Association (NYHA) II to ambulatory IV ischemic heart failure patients with ejection fraction 15%-40% to support regulatory submission for the Parachute device to China Food and Drug Administration (CFDA).

The Parachute device provides the first minimally invasive catheter-based treatment to partition the damaged muscle, excluding the non-functional heart segment from the healthy, functional segment to decrease overall volume of the left ventricle and restore its geometry and function.

"The company said results from the Parachute China trial will be presented at the China Interventional Therapeutics (CIT) 2015 conference, which will take place between 19-22 March in Beijing, China."

Primary endpoint of the trial is reduction in left ventricular end systolic volume index (LVESVi) at three months, which will be analysed at an echocardiography core lab, Yale Cardiovascular Research Group.

The company said results from the Parachute China trial will be presented at the China Interventional Therapeutics (CIT) 2015 conference, which will take place between 19-22 March in Beijing, China.

CardioKinetix president Maria Sainz said: "The completion of enrolment in the China study is a major milestone for CardioKinetix.

"We are highly encouraged by the Chinese investigators’ enthusiasm for the Parachute device and commitment to enrolling the trial so efficiently, and we look forward to releasing the results this spring."

In the trial, Fu Wai Hospital chief cardiologist Dr Gao Runlin is serving as principal investigator and Heart Center and Department of Cardiology PKU-1st Hospital director Dr Huo Yong, and Cardiovascular Institute vice-president Dr Yang Yuejin are serving as co-principal investigators.